February 23rd 2023
February 23rd 2023
Dr Clifford Goodman: A Look at the Present and Future of Value Frameworks
July 22nd 2017Value frameworks are tools used to clarify cost-benefit tradeoffs in healthcare decisions, which means they can look very different depending on their intended audience, according to Clifford Goodman, PhD, moderator at the ACO Coalition spring live meeting in Scottsdale, Arizona, and senior vice president and director at the Center for Comparative Effectiveness Research at the Lewin Group.
Watch
New Flow Cytometry-Based Test Approved for Certain Leukemias and Lymphomas
July 3rd 2017A new liquid biopsy test that uses flow cytometry to detect cancer cells has been FDA approved for chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms.
Read More
Caps on Medical Malpractice Awards Move Through House
June 29th 2017Tort reform has been on doctors' wish lists for decades. Supporters of reform say it would reduce frivolous claims and stop doctors from practicing defensive medicine, while some consumer groups say doctors should not be insulated from liability for egregious errors.
Read More
ICER Releases Update Due to New Evidence About PCSK9 Inhibitor Effectiveness
June 15th 2017On June 14, 2017, The Institute for Clinical and Economic Review (ICER) added a “New Evidence Update” to the 2015 review of the comparative clinical effectiveness and value of PCSK9 inhibitors for management of high cholesterol.
Read More
Daratumumab With Standard Regimen Improves PFS in Multiple Myeloma, Independent of Cytogenetic Risk
June 5th 2017Updated results from the POLLUX and CASTOR trials, presented at the 2017 American Society of Clinical Oncology Annual Meeting, have found that including daratumumab in standard-of-care regimens prolonged progression-free survival (PFS) and improved the depth of response, independent of the patients’ cytogenetic risk.
Read More